Recell system under study for soft-tissue reconstruction

Enrollment in a trial to evaluate the Recell system for soft-tissue reconstruction has been completed, according to a press release from Avita.

The Recell system was FDA approved for treatment of acute thermal burns in adults in 2018, and the indication was expanded in 2021 for use in combination with meshed autografting to include treatment of acute full-thickness thermal burn wounds in pediatric patients.

The system uses the patient’s own skin cells to prepare an autologous suspension that is sprayed onto the area of treatment and is designed for point-of-care delivery or for use in combination with autografts.

Topline data from the trial are expected in 2022, the release said.

“[W]ith FDA approval of this [new] indication, we expect to expand the use of Recell to include all acute wounds,” Mike Perry, PhD, CEO of Avita Medical, said in the release.

The Recell system is CE marked in Europe and registered by the Therapeutic Goods Administration, according to the release.